Amy Cassedy

Dec 21, 2024 | acrjournals.onlinelibrary.wiley.com | Ilaria Maccora |Hermine I Brunner |Amy Cassedy |Mekibib Altaye |Megan Quinlan‐Waters |Daniel Lovell | +2 more

INTRODUCTION Juvenile dermatomyositis (JDM) is a rare autoimmune disease characterized by symmetric proximal muscle weakness, a characteristic rash, and a risk for calcinosis.1, 2 Systemic immunosuppression is generally needed for JDM treatment to avoid severe disability and a decreased quality of life.1, 3, 4 Standard treatment includes corticosteroids (intravenous and oral), intravenous immunoglobulin (IVIG), methotrexate, and hydroxychloroquine.1, 5, 6 However, not all patients respond to...